Hackensack Meridian Health The company announced a partnership with CancerIQ, an oncology-focused precision medicine company, to launch a Cancer Risk and Early Detection Program at the health system’s Hennessy Institute for Cancer Prevention and Applied Molecular Medicine with the aim of improving early diagnosis, treatment and prevention.
The program integrates advanced technology, genomics and AI into real-time electronic health record (EHR) workflows to streamline comprehensive cancer risk assessments and individualized care plans.
The HMH program includes the CancerIQ tool, which collects personal and family medical history and lifestyle factors to identify individuals at high risk for cancer.
Patients identified as high risk are offered individualized early detection and prevention strategies.
The program also utilizes molecular cancer screening techniques, such as liquid biopsy, to detect cancer at its earliest stages by identifying genetic material released into the bloodstream.
“This new program breaks new ground in cancer research, from preventing cancer in people with genetic risk factors to detecting cancer earlier and reducing cancer recurrence,” Andre Goy, president and executive director of the John Tueller Cancer Center, said in a statement.
The initiative is part of HMH’s Hennessy Institute for Cancer Prevention and Applied Molecular Medicine (HICAP) and will be offered at a new cancer center in Totowa, New Jersey, with plans to expand to Clifton, New Jersey in early 2025.
Larger trends
World Health Organization Estimated value Between 30% and 50% of all cancer cases are preventable, and improved access to genetic testing will allow us to screen, test, and identify more people who may be at risk.
In January Interview MobiHealthNewsFounder and CEO of CancerIQ, Faye Ayodele, explained the benefits of personalized care plans and advanced technology to help healthcare professionals detect cancer early.
“As science advances, we’ll know more about the relationship between cancer and genes and other factors, and we’ll be able to act on that knowledge. Essentially, what we’re doing is empowering everyday health care providers to use that information to design individualized care plans,” Ayodele said.
Ensure Cancer IQ Raised $14 million in Series B in 2020, two years later Series A funding of $4.8 million.
The Chicago-based company said Thursday it had secured growth funding from Decathlon Capital Partners but did not disclose the amount raised.
Other companies in the precision oncology space include: GE HealthCare and BAMF Health recently partnered to enhance theranostics adoption.
Theranostics combines diagnostic imaging and targeted therapy to identify and directly treat cancer cells, enabling personalized treatment.
